Joseph P. Hagan Acquires 50,000 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was purchased at an average cost of $1.09 per share, with a total value of $54,500.00. Following the completion of the purchase, the chief executive officer now directly owns 260,808 shares in the company, valued at $284,280.72. This represents a 23.72 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Regulus Therapeutics Price Performance

RGLS stock opened at $1.00 on Friday. The stock’s 50 day moving average price is $1.46 and its 200 day moving average price is $1.54. Regulus Therapeutics Inc. has a 1 year low of $0.83 and a 1 year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds have recently modified their holdings of RGLS. Point72 Asset Management L.P. purchased a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $1,403,000. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics during the 3rd quarter worth $10,154,000. Barclays PLC lifted its stake in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the period. State Street Corp grew its position in shares of Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock valued at $1,572,000 after purchasing an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after purchasing an additional 37,480 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.